MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Bifidobacterium animalis is a gram-positive, anaerobic, rod-shaped bacterium of the Bifidobacterium genus which can be found in the large intestines of most mammals, including humans. Bifidobacterium animalis and Bifidobacterium lactis were previously described as two distinct species. Presently, both are considered B. animalis with the subspecies Bifidobacterium animalis subsp. animalis and Bifidobacterium animalis subsp. lactis. Both old names B. animalis and B. lactis are still used on product labels, as this species is frequently used as a probiotic. In most cases, which subspecies is used in the product is not clear.
== Fluorescence == The quinine in tonic water will fluoresce under ultraviolet light. In fact, quinine will visibly fluoresce in direct sunlight against a dark background. The quinine molecules release energy as light instead of heat, which is more common. The state is not stable, and the molecules will immediately return to a ground state and no longer glow once the UV source is removed.
== External links == Understanding Pompe Disease - US National Institute of Arthritis and Musculoskeletal and Skin Diseases AGSD — Association of Glycogen Storage Disease in the United States AGSD-UK — Association of Glycogen Storage Disease in the UK AMDA — Acid Maltase Deficiency Association (Pompe disease) IPA — International Pompe Association IamGSD — International Association for Muscle Glycogen Storage Disease
Sources: en.wikipedia.org
Allothreonine is an amino acid with the formula CH3CH(OH)CH(NH2)CO2H. It is the diastereomer of the amino acid threonine. Like most other amino acids, allothreonine is a water-soluble colorless solid. Although not one of the proteinogenic amino acids, it has often been the subject for the synthesis of novel proteins using an expanded genetic code. Racemic allothreonine can be produced in the laboratory from bromomethoxybutyric acid.
A more commonly used parameter is the half-life T1/2. Given a sample of a particular radionuclide, the half-life is the time taken for half the radionuclide's atoms to decay. For the case of one-decay nuclear reactions:
in a gathering or a date, are known as dining, and large dining events where many people are invited to eat food together are known as banquets or feasts. The craft of preparing and presenting meals for formal eating is called culinary arts, and the person performing such tasks is known as a cook, chef or cater depending on the respective nature of food service. Physicians and dieticians consider eating a healthy diet essential for maintaining peak physical condition. Some individuals may reduce their amount of dietary intake, which may be a result of a voluntary choice as part of dieting lifestyle or as fasting for reasons of religious food prohibition, abstinence or political protest (i.e. a hunger strike). Limited consumption or rationing may also be due to logistical reasons such as a food shortage or a famine, in which case it will lead to starvation and undernutrition. On the contrary, overeating and excessive intake of calories (overnutrition) may lead to obesity and associated health problems, and while the reasons behind it are myriad, its prevalence in the developed world has led some public health professionals to declare an "obesity epidemic".
Sources: en.wikipedia.org
10 October – The Scottish Government shelves plans for the early release of long term prisoners following concerns raised by victims groups, but will reduce the automatic early release for short term prisoners from the point of 50% completion of their sentence to 40%. 11 October – It is reported that Education Secretary Jenny Gilruth has withheld £145.5m in funding to all councils because of a disagreement over cuts to the number of teachers. 12 October – Alex Salmond, former first minister of Scotland, dies aged 69 in North Macedonia. 13 October – Flags are lowered to half-mast at the Scottish Parliament following the death of former First Minister Alex Salmond the previous day. MSP John Mason is expelled from the SNP after posting on Twitter that there was "no genocide" in Gaza. 14 October – The Scottish Government confirms that ferry fares in Scotland will increase by 10% from 1 January 2025. Glasgow City Council unveils plans to make improvements to the city centre, with the changes scheduled to begin in 2025. 16 October – Following trial and conviction at the High Court in Edinburgh, Jamie Boulton is sentenced to life imprisonment with at least 18 years in custody for the stabbing murder of Gary O'Neill at a flat in Leith in June 2023. 17 October – BBC One programme Crimewatch Live makes a fresh appeal for information leading to the discovery of the remains of Suzanne Pilley, who was murdered by her ex-partner in 2010.
Different cell types within adipose tissue exhibit distinct DNA methylation patterns. Mature adipocytes and adipose progenitor cells (ASPCs) show a high degree of hypomethylation, affecting more than 50% of their regulatory regions. This hypomethylation is associated with the activation of genes involved in triglyceride synthesis, such as glycerol‑3‑phosphate acyltransferase 1 (GPAM). In contrast, myeloid cells display approximately 73% hypermethylated regions, reflecting an epigenetic program opposite to that of the adipocytic lineage. Overall, there is a direct relationship between DNA demethylation and gene expression, whereby highly expressed genes tend to exhibit low methylation levels. These epigenetic patterns contribute to defining the functional identity of the different cell types within subcutaneous adipose tissue (SAT).
When an action potential is triggered, the membrane potential abruptly shoots upward and then equally abruptly shoots back downward, often ending below the resting level, where it remains for some period of time. The shape of the action potential is stereotyped; this means that the rise and fall usually have approximately the same amplitude and time course for all action potentials in a given cell. (Exceptions are discussed later in the article) In most neurons, the entire process takes place in about a thousandth of a second. Many types of neurons emit action potentials constantly at rates of up to 10–100 per second. However, some types are much quieter, and may go for minutes or longer without emitting any action potentials.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.